1. Show article details.

    Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business

    PR Newswire – 12:30 PM ET 02/27/2015

    POTTERS BAR, England and PITTSBURGH, Feb. 27, 2015Mylan N.V. and Mylan Inc. (MYL) today announced the successful completion of the acquisition of Abbott Laboratories' (ABT) non-U.S. developed markets specialty and branded generics business. Executive Chairman Robert J. Coury commented, "Today marks the beginning of the next exciting chapter of growth for Mylan.

  2. Show article details.

    Abbott Declares 365th Consecutive Quarterly Dividend

    PR Newswire – 10:36 AM ET 02/20/2015

    ABBOTT PARK, Ill., Feb. 20, 2015 The board of directors of Abbott today declared a quarterly common dividend of 24 cents per share. This marks the 365th consecutive quarterly dividend to be paid by Abbott since 1924.

  3. Show article details.

    Abbott to Present at Cowen and Company 35th Annual Health Care Conference

    PR Newswire – 9:00 AM ET 02/19/2015

    ABBOTT PARK, Ill., Feb. 19, 2015Abbott will present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3, 2015. Scott White, senior vice president, international nutrition, and Brian Yoor, vice president, investor relations, will participate in the conference at 9 a.m. Central time.

  4. Show article details.

    Time for Boston Scientific shares to break out?

    MarketWatch – 12:33 PM ET 02/18/2015

    J&J lawsuit was' major overhang' on stock, analysts say. For much of the past decade, Boston Scientific Corp. (BSX) has struggled to keep up with the valuations of its rivals in the medical device-making business, its stock languishing in the teens and even single digits at times while competitors' shares fly at much higher levels. On Tuesday Boston Scientific (BSX) removed what many stock analysts say was a "major overhang" on its stock by reaching a $600 million settlement in a $7 billion lawsuit,...

  5. Show article details.

    Zoetis Profit Up 20%, 2015 Outlook Cut Slightly

    DJ Business News – 7:54 AM ET 02/11/2015

    Zoetis Inc. (ZTS) said its fourth-quarter earnings rose 20% on stronger revenue, though the animal-health company was the latest to have currency fluctuations weigh on growth. For 2015, the company lowered its revenue outlook slightly to $4.8 billion to $4.9 billion, from its previous estimate for $4.85 billion to $4.95 billion and affirmed its per-share earnings guidance. The updated outlook reflects foreign-exchange rates, the company's recent $255 million acquisition of...

  6. Show article details.

    RBCC Joint Venture Partner n3D to Present Latest 3D Bioprinting Research in Washington, D.C.

    Business Wire – 5:00 AM ET 02/10/2015

    Rainbow Coral Corp.’s (RBCC) 3D bioprinting joint venture partner Nano3D Biosciences will present a new abstract detailing the latest breakthroughs made using its technology in Washington, D.C. on Wednesday at the 4th annual Society for Laboratory Automation and Screening Conference and Exhibition.

  7. Show article details.

    RPT-INSIGHT-U.S. companies may not be fleeing due to high tax rate, Reuters analysis shows

    Reuters – 7:00 AM ET 02/09/2015

    * Wave of inversion deals had many causes, experts say. * Earnings stripping, foreign profits seen as key. * Motivation for deals not clearly linked to tax rate. * Obama's budget last week proposed anti-inversion steps. By Kevin Drawbaugh.

  8. Show article details.

    U.S. companies may not be fleeing due to high tax rate, Reuters analysis shows

    Reuters – 1:09 AM ET 02/09/2015

    When a series of big U.S. companies last year moved to reincorporate abroad in inversion deals, some Republican lawmakers and tax policy critics blamed the high U.S. corporate tax rate.

  9. Show article details.

    INSIGHT-U.S. companies may not be fleeing due to high tax rate, Reuters analysis shows

    Reuters – 1:00 AM ET 02/09/2015

    * Wave of inversion deals had many causes, experts say. * Earnings stripping, foreign profits seen as key. * Motivation for deals not clearly linked to tax rate. * Obama's budget last week proposed anti-inversion steps. By Kevin Drawbaugh.

  10. Show article details.

    RBCC and n3D Pursue New Partnership Opportunities After Highly Successful 3D Bioprinting Exhibit at Biotech Showcase 2015

    Business Wire – 5:00 AM ET 02/05/2015

    Rainbow Coral Corp. (RBCC) and Nano3D Biosciences are lining up new 3D bioprinting opportunities and potential partnerships following a highly successful product exhibition last month at Biotech Showcase 2015 in San Francisco.

  11. Show article details.

    Abbott to Present at Leerink Global Healthcare Conference

    PR Newswire – 9:00 AM ET 02/04/2015

    ABBOTT PARK, Ill., Feb. 4, 2015Abbott will present at the Leerink Global Healthcare Conference on Thursday, Feb. 12, 2015. A live audio webcast of the presentation will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com.  An archived edition of the presentation will be available later that day.

  12. Show article details.

    Insulet Extends Exclusive Agreement for Blood Glucose Monitoring

    Market Wire – 4:01 PM ET 02/03/2015

    02/03/15 -- Insulet Corporation (PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced that it has extended its ongoing exclusive agreement with Abbott Laboratories (ABT) to continue integration of the Abbott FreeStyle® blood glucose monitoring technology with Insulet's OmniPod System.

  13. Show article details.

    Mylan to Buy Businesses From Famy Care for $750 Million

    DJ Business News – 7:36 AM ET 02/02/2015

    Mylan Inc. (MYL) has agreed to buy certain women's health-care businesses from India's Famy Care Ltd. for $750 million in cash, in a move that will position Mylan as a leading provider of contraceptives in emerging markets. Mylan has partnered with Famy in developed markets including North America, Europe and Australia since 2008. Mumbai-based Famy is a producer of oral and injectable contraceptive pills and intrauterine devices, among other items. Under the terms of the deal, which...

  14. Show article details.

    AbbVie Hepatitis C Drug Predictions Disappoint

    DJ Business News – 9:25 AM ET 01/30/2015

    Most pharmaceutical-company investors would be thrilled at the prospect of a new drug reaching annual sales of $2 billion to $3 billion. But the hit AbbVie Inc. (ABBV) shares took Friday shows how high expectations have become for new hepatitis C drugs. AbbVie Inc. Chief Executive Richard Gonzalez said Friday he expects the company's new hepatitis C treatment, Viekira Pak, to be selling at an annualized clip of more than $3 billion by the end of 2015. "We believe we have potential to...

  15. Show article details.

    Abbott Launches New Options for People with Cataracts in the United States

    PR Newswire – 9:00 AM ET 01/30/2015

    ABBOTT PARK, Ill., Jan. 30, 2015 Two new intraocular lenses that restore vision to people with cataracts are now available in the United States. The new TECNIS® Multifocal IOLs, developed by Abbott, provide people with cataracts options to have a full range of near, intermediate and distance vision, while customizing their treatment based on their personal vision needs and lifestyle.

  16. Show article details.

    Drugmaker AbbVie beats estimates as Humira sales rise

    Reuters – 8:42 AM ET 01/30/2015

    U.S. drugmaker AbbVie Inc's (ABBV) revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent. The company, however, reported a net loss of $810 million, or 51 cents per share, for the fourth quarter, mainly due to a charge related to its aborted $55 billion deal to buy British drugmaker Shire Plc.

  17. Show article details.

    AbbVie Tops Expectations, Gives First Look at Viekira Sales

    DJ Business News – 8:42 AM ET 01/30/2015

    AbbVie Inc. (ABBV) on Friday reported fourth-quarter results that topped Wall Street expectations amid strong sales growth, even expenses related to its scuttled merger with Shire PLC (SHPG) dragged the company to a loss. The company's long-awaited multidrug regimen for hepatitis C, Viekira Pak, registered $48 million in sales in the days following its Dec. 19 approval by the U.S. The all-oral product is expected to generate more than $2.5 billion in sales for AbbVie (ABBV) in 2015, analysts...

  18. Show article details.

    Updates, advisories and surprises

    MarketWatch – 5:31 PM ET 01/29/2015

    Google CFO says currency issues are' not going away'. Google Inc. CFO Patrick Pichette told analysts that currency issues are "not going away," based on recent currency movements compared with the U.S. dollar. "Everybody should be considering it," Pichette said, noting that the company saw a material impact in the fourth quarter from the strong dollar but that its hedging program did what it is supposed to do.

  19. Show article details.

    Abbott CEO losing no sleep over stronger dollar

    Reuters – 3:15 PM ET 01/29/2015

    Abbott Laboratories' (ABT) chief executive officer is not worried about the stronger dollar, telling analysts on Thursday his company will better withstand its painful effects than rivals due to its European factories and growing sales of nutritional products, medical diagnostics and medical optics.

  20. Show article details.

    Mylan Shareholders Overwhelmingly Approve Agreement Implementing Acquisition of Abbott's Non-U.S. Developed Markets Specialty and Branded Generics Business

    PR Newswire – 11:18 AM ET 01/29/2015

    PITTSBURGH, Jan. 29, 2015 Mylan Inc. (MYL) announced that at a Special Meeting of Shareholders held Jan. 29, 2015, Mylan's shareholders overwhelmingly approved the agreement implementing Mylan's pending acquisition of Abbott's non-U.S. developed markets specialty and branded generics business and reorganization in the Netherlands in an all-stock transaction.


Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.